AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AstraZeneca PLC Director's Dealing 2020

Feb 7, 2020

5229_dirs_2020-02-07_08cc773e-b386-435e-b732-33d2f2ff68ce.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aevi Genomic Medicine, Inc. (GNMX)
CIK: 0001138776
Period of Report: 2019-12-19

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: MedImmune Ltd (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12946900	Indirect

Footnotes

F1: All of these securities are owned by MedImmune Limited, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by MedImmune Limited, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.